The use of 68 Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk

Jinhui Yang; Yongxiang Tang; Chuanchi Zhou; Ming Zhou; Jian Li; Shuo Hu

doi:10.1002/pros.24475

The use of ⁶⁸ Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk

Prostate. 2023 Apr;83(5):430-439. doi: 10.1002/pros.24475. Epub 2022 Dec 21.

Authors

Jinhui Yang¹, Yongxiang Tang¹, Chuanchi Zhou², Ming Zhou¹, Jian Li¹, Shuo Hu^{1

3

4}

Affiliations

¹ Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
³ Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁴ National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University, Changsha, Hunan, China.

PMID: 36544382
DOI: 10.1002/pros.24475

Abstract

Background: Prostate imaging reporting and data system (PI-RADS) category 3 lesions represent a "gray zone," having an equivocal risk of presenting as clinically significant prostate cancer (csPCa). ⁶⁸ Ga-labelled prostate-specific membrane antigen (⁶⁸ Ga-PSMA) positron emission tomography/computed tomography (PET/CT) has been identified as a diagnostic tool that can help to predict cases of primary PCa. We aimed to explore diagnostic value of ⁶⁸ Ga-PSMA PET/CT for csPCa in PI-RADS 3 lesions to aid in decision-making and avoid unnecessary biopsies.

Methods: A total of 78 men with PI-RADS 3 lesions who underwent both ⁶⁸ Ga-PSMA PET/CT and transrectal ultrasound/magnetic resonance imaging (MRI) fusion-guided biopsy were enrolled. Images were analyzed by respective physicians who were blinded to the pathological results. Receiver operating characteristic (ROC) curve analysis and decision curve analysis were used to evaluate the diagnostic performance of univariate and multivariate analyses.

Results: A total of 26/78 men had pathologically confirmed csPCa. A lower ADCT/ADCCLP (0.65 vs. 0.71, p = 0.018), smaller prostate volume (25.27 vs. 42.79 ml, p < 0.001), lower free prostate-specific antigen/total prostate-specific antigen (0.11 vs. 0.16, p < 0.001), higher PSA level (13.45 vs. 7.90 ng/ml, p = 0.001), higher PSA density (0.40 vs. 0.16 ng/ml² , p < 0.001), higher SUVmax (9.80 vs. 4.40, p < 0.001) and SUVT/BGp (2.41 vs. 1.00, p < 0.001) were associated with csPCa. ROC analysis illustrated the improvement in SUVmax and SUVT/BGp compared with all independent and combined clinical features as well as multiparametric magnetic resonance imaging (mpMRI) features for csPCa detection. The net benefits of SUVmax and SUVT/BGp were superior to those of other features, respectively. With cutoff values of 5.0 for SUVmax and 1.4 for SUVT/BGp, the diagnostic sensitivity and specificity for csPCa were 96.2%, 100% and 80.8%, 84.6%, respectively.

Conclusion: ⁶⁸ Ga-PSMA PET/CT is potentially capable of stratifying men with PI-RADS 3 lesions according to the presence of csPCa and has better performance than the model established based on clinical and mpMRI features.

Keywords: PET/CT; PI-RADS; PSMA; clinically significant prostate cancer; prostate cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Image-Guided Biopsy / methods
Magnetic Resonance Imaging / methods
Male
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen* / analysis
Prostatic Neoplasms* / pathology
Retrospective Studies

Substances

Prostate-Specific Antigen
gallium 68 PSMA-11

Abstract

Publication types

MeSH terms

Substances

Grants and funding